Logo
Euro Gen DSIP, 5mg

Euro Gen DSIP, 5mg

Euro-Gen

Research chemical / peptide reagent
  • Supplied and labelled as a research Use Only peptide reagent and not as a medicinal product, medical device, cosmetic or food.
  • Not authorised or licensed by the MHRA, EMA, FDA or other regulatory bodies for any therapeutic indication.
  • Use is governed by general chemical and biological safety regulations and institutional policies applicable to laboratory reagents in the jurisdiction of use.
  • Researchers and institutions are responsible for ensuring that any experimental use complies with local laws, ethical approvals, and relevant professional or anti Doping codes.
Neuropeptide (Delta Sleep-Inducing Peptide) for in vitro research

Description

Euro-Gen DSIP, 5mg is a synthetic research peptide supplied as a lyophilised powder in a sealed vial, intended strictly for in vitro testing and laboratory research. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring neuropeptide first identified in the 1970s and studied primarily for its role in sleep regulation and stress responses. It is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu and an approximate molecular weight of 848.8 g/mol. Research has explored DSIP’s potential influence on sleep architecture, stress adaptation, endocrine regulation, cardiovascular parameters and pain modulation, but its mechanisms remain incompletely understood and it is not an approved medicine. The Euro-Gen product is marketed as high-purity research-grade DSIP and is clearly labelled for research use only, not for human or veterinary administration.

Bnefits

  • Provides a defined 5 mg quantity of DSIP neuropeptide in lyophilised form for reproducible in vitro and preclinical research designs.
  • DSIP is a well-characterised nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a substantial preclinical literature base in sleep, stress and neuroendocrine research.
  • Marketed as high-purity (typically >99% by HPLC) research-grade material suitable for analytical chemistry, biochemical and cell-based assays.
  • Lyophilised presentation in a sealed vial supports peptide stability during storage and transport prior to reconstitution in a controlled laboratory setting.
  • Can be used as a tool compound in studies of sleep regulation, neuroprotection, stress resilience, endocrine modulation and cardiovascular or pain-related pathways, as permitted by institutional approvals.
  • Clearly designated as research-use-only, helping laboratories maintain separation between experimental reagents and regulated medicinal products.

Indications

  • No approved therapeutic indications; Euro-Gen DSIP, 5mg is not licensed as a medicine or medical device.
  • Intended exclusively for in vitro and preclinical laboratory research involving delta sleep-inducing peptide and its analogues.
  • Suitable for use as a reference or tool peptide in studies of sleep regulation, circadian biology, stress response, neuroprotection, endocrine and cardiovascular function, and pain modulation.
  • May be used in ethically approved animal or ex vivo models, where permitted by local regulations and institutional review, solely as a research reagent.
  • Not for human or veterinary injection, ingestion, inhalation, topical application or any other route of bodily administration.

Composition

  • Active research ingredient: Delta Sleep-Inducing Peptide (DSIP), a synthetic nonapeptide.
  • Amino-acid sequence (one-letter code): WAGGDASGE (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu).
  • Empirical molecular formula: C35H48N10O15.
  • Approximate molecular weight: 848.8 g/mol.
  • CAS Registry Number: 62568-57-4.
  • Supplied as lyophilised (freeze-dried) peptide powder; any trace excipients used during lyophilisation are not typically specified and may vary by batch.
  • No solvent, diluent, bacteriostatic agent or buffer is supplied in the vial; reconstitution media are provided separately by the end user according to experimental needs.

Formulation

  • Lyophilised synthetic DSIP peptide powder in a sterile, sealed glass vial containing a nominal 5 mg of peptide.
  • Research-grade purity (typically >99% by HPLC according to supplier information) intended for laboratory use.
  • Designed for reconstitution with a suitable sterile laboratory-grade diluent (e.g. bacteriostatic water, sterile saline, or assay buffer) by trained personnel following institutional SOPs.
  • Formulated and labelled solely as a research reagent and not as a medicinal dosage form for clinical administration.

Packaging

  • Single 5 mg DSIP lyophilised peptide vial with rubber stopper and crimped cap, labelled with product name (Euro-Gen DSIP, 5mg), brand and research-only status.
  • Supplied within secondary protective packaging (e.g. cardboard carton or padded mailer) to minimise damage during shipping.
  • Accompanied by online product information from distributors describing DSIP’s research background (e.g. roles in sleep regulation, stress modulation, neuroprotection and analgesia) and highlighting its research-use-only designation.
  • No printed patient leaflet is supplied, as the product is not intended or labelled for human therapeutic use.

Usage

  • For in vitro testing and laboratory research only; to be handled exclusively by suitably qualified and authorised laboratory personnel.
  • Do not inject, ingest, inhale, or apply to humans or animals; any form of bodily administration is expressly prohibited and outside the product’s intended scope.
  • Before first use, visually inspect the vial to ensure integrity of the container and lyophilised cake; do not use if the vial is cracked, the seal compromised, or the contents appear grossly abnormal.
  • Reconstitute the lyophilised peptide with an appropriate sterile, laboratory-grade diluent according to your institution’s SOPs and the requirements of the experimental protocol (e.g. target concentration, buffer composition, pH).
  • Use aseptic technique during all reconstitution and sampling steps to avoid contamination and preserve experimental reliability.
  • Document batch/lot number, reconstitution details (diluent, concentration, date) and storage conditions in laboratory records for traceability.
  • Store any reconstituted solution according to internal guidelines (e.g. aliquoted and refrigerated or frozen), avoiding repeated freeze–thaw cycles.
  • Dispose of unused peptide, reconstituted solutions, vials, syringes, needles and other contaminated materials as chemical/biological laboratory waste in accordance with institutional and regulatory requirements.
  • Do not use marketing or online product descriptions as medical guidance; DSIP remains an investigational research peptide and is not approved for therapeutic use.

Contraindications

  • Any use involving administration to humans or animals (e.g. via injection, ingestion, inhalation or topical application) is contraindicated and outside the product’s stated research-only purpose.
  • Should not be used as a substitute for licensed medicines in the management of sleep disorders, stress-related conditions, pain, or any other clinical indication.
  • Not suitable for laboratories without adequate facilities, biosafety measures, PPE, and waste-disposal procedures for handling synthetic peptides.
  • Individuals with known hypersensitivity to peptides or specific excipients should avoid direct contact and follow occupational health advice.
  • Not to be used for doping, performance enhancement, or any purpose intended to evade anti-doping regulations in sport or competition.

Adverse Effects

  • No formal adverse effect profile is established for this commercial preparation in humans or animals, as it is not intended for administration.
  • Accidental laboratory exposure (e.g. skin or eye contact, inhalation of dust/aerosol, or inadvertent ingestion) may cause non-specific irritation or sensitisation; affected individuals should follow standard laboratory first-aid procedures (e.g. thorough rinsing with water) and seek medical evaluation if symptoms persist.
  • Unauthorised self-administration or off-label clinical use of research-grade DSIP may carry unpredictable risks, including contamination, dosing error, neuroendocrine disruption, and unknown long-term safety; such behaviour is strongly discouraged and lies outside intended use.
  • Laboratory staff should consult institutional safety data and risk assessments for peptides and use appropriate PPE (e.g. gloves, eye protection, lab coats) to minimise exposure.

Storage Conditions

  • Store unopened vials in a cool, dry place protected from direct light and moisture, following any specific temperature recommendations provided by the supplier (commonly refrigerated or frozen for extended stability).
  • Avoid prolonged exposure to elevated temperatures and repeated temperature cycling; do not use if signs of degradation or container damage are present.
  • After reconstitution, store solutions according to internal SOPs (e.g. aliquoted and kept at 2–8 °C for short-term use or ≤ −20 °C for longer-term storage) and avoid repeated freeze–thaw cycles.
  • Keep vials and any reconstituted solutions out of reach of unauthorised personnel and clearly segregated from licensed medicinal products, foodstuffs and cosmetics.
  • Adhere to any expiry or best-before dates supplied by the manufacturer or distributor, and dispose of expired or compromised material as laboratory waste in compliance with local regulations.

Duration

Not applicable. Euro-Gen DSIP, 5mg is a research reagent with no authorised clinical indications, treatment regimens or dosing schedules in humans or animals; any therapeutic use would be outside its intended purpose and contrary to supplier guidance.

Onset

Not applicable to clinical endpoints. In experimental systems, any observed biochemical or physiological effects of DSIP depend on the specific in vitro or preclinical model, concentration, exposure duration and protocol parameters, and cannot be extrapolated to human therapeutic effects or timelines.

Browse more Research chemical / peptide reagent

Top Treatments

Top Cities in the UK